Phio Pharmaceuticals Corp.: CVI Investments, Inc. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
CVI Investments, Inc. filed an amended Schedule 13G with the SEC disclosing a change to its passive stake in Phio Pharmaceuticals Corp. The amendment, accession number 0001649553-26-000139, updates the investor's previously reported beneficial ownership position in the clinical-stage immuno-oncology company. Schedule 13G filings are required of investors holding more than 5% of a company's shares who do not seek control, so the revision signals a shift in CVI's holdings rather than activist intent. The exact revised share count and percentage were not specified in the filing headline. Investors will watch for the full filing details to gauge whether CVI increased or trimmed its position, a signal of institutional confidence in Phio's pipeline.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
CVI Investments, Inc., Phio Pharmaceuticals Corp.